Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study

BACKGROUND: BRAF mutation plays a rare but aggressive oncogenic role in non-small cell lung cancer (NSCLC) patients. The controversy of first-line chemotherapy in patients with different BRAF mutations exists. Here, we identified 41 stage IIIB/IV NSCLC patients with BRAF mutation from 3,669 NSCLC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Lei, Wang, Wen-Xian, Zhu, You-Cai, Pu, Xing-Xiang, Fang, Yong, Wang, Hong, Zhuang, Wu, Zhang, Yin-Bin, Wang, Li-Ping, Xu, Chun-Wei, Fang, Mei-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798181/
https://www.ncbi.nlm.nih.gov/pubmed/35117215
http://dx.doi.org/10.21037/tcr-20-480

Ejemplares similares

Ejemplares similares